| Number: GOG 9920 |
Principal Investigator: Mutch, David |
| Title: A Phase I Study of IV Doxorubicin Plus Intraperitoneal (IP) Paclitaxel and IV or IP Cisplatin in Endometrial Cancer Patients at High Risk for Peritoneal Failure |
| Description: The purpose of this study is to test the safety of a chemotherapy treatment that includes both intravenous (IV – given by vein) and intraperitoneal (IP- given directly into the abdomen) administration of drugs for patients with high-risk endometrial cancer. Currently, intraperitoneal chemotherapy i...MORE |
| ___________________________________________________________________________________________________ |
| Number: GOG 261 |
Principal Investigator: Mutch, David |
| Title: A Randomized Phase III Trial of Paclitaxel Plus Carboplatin Versis Ifosfamide Plus Paclitaxel in Chemotherapy-Naive Patients with newly Diagnosed Stage I-IV Persistent or Recurrent Carcinosarcoma (Mixed Mesodermal Tumors) of the Uterus or Ovary |
| Description: The purpose of this study is to compare the drugs carboplatin and paclitaxel to a standard treatment for your type of cancer (paclitaxel plus ifosfamide and mesna). Based on results of other clinical trials, researchers think that the combination of carboplatin and paclitaxel may be as effective as...MORE |
| ___________________________________________________________________________________________________ |
| Number: GOG 258 |
Principal Investigator: Mutch, David |
| Title: A Randomized Phase III Trial of Cisplatin and Tumor Volume Directed Irradiation Followed by Carboplatin and Paclitaxel vs. Carboplatin and Paclitaxel for Optimally Debulked, Advanced Endometrial Carcinoma |
| Description: Patients with endometrial cancer have been treated with radiation and chemotherapy. Today most women with endometrial cancer whose cancer has spread outside the uterus generally receive chemotherapy. Women who have disease outside the uterus may also receive radiation to the areas where the diseas...MORE |
| ___________________________________________________________________________________________________ |
| Number: GOG 229K |
Principal Investigator: Mutch, David |
| Title: A Phase II Evaluation of BIBF 1120 (IND #113086) In The Treatment of Recurrent or Persistent Endometrial Carcinoma |
| Description: The purpose of this study is to determine the effectiveness of the investigational drug BIBF 1120 in treating your type of cancer and to determine the types and severity of side effects caused by this treatment. BIBF 1120 is not an FDA (Food and Drug Administration) approved drug and therefore the u...MORE |
| ___________________________________________________________________________________________________ |
| Number: GOG 131H |
Principal Investigator: Mutch, David |
| Title: A Phase II Evaluation of Ixabepilone In The Treatment of Recurrent Or Persistent Leiomyosarcoma Of The Uterus |
| Description: The purpose of this study is to find out if the study drug, Ixabepilone, works in treating your type of cancer and to find out what side effects are caused by treatment with this drug.
The drug ixabepilone has been approved by the FDA (Food and Drug Administration) for use in patients with breast...MORE |
| ___________________________________________________________________________________________________ |
| Number: GOG 130F |
Principal Investigator: Mutch, David |
| Title: A Phase II Evaluation of Ixabepilone (IND #710428) in the Treatment of Recurrent or Persistent Carcinosarcoma of the Uterus (NCI version 11/29/10) |
| Description: The purpose of this study is to find out if the study drug, Ixabepilone, works in treating your type of cancer and to find out what side effects are caused by treatment with this drug....MORE |
| ___________________________________________________________________________________________________ |
| Number: 201210087 |
Principal Investigator: Novetsky, Akiva |
| Title: Etiology of fever in non-operative gynecologic oncology patients |
| ___________________________________________________________________________________________________ |
| Number: 201105400 |
Principal Investigator: Mutch, David |
| Title: Formation of a Tissue Bank for Gynecologic Malignancies |
| Description: The purpose of this study is to collect specimens (i.e., tissue obtained during surgery and/or blood) and related information from women who are undergoing surgery for a gynecologic condition. Specimens and related information that are collected for this research study will be used for future cance...MORE |
| ___________________________________________________________________________________________________ |
| Number: 201103375 |
Principal Investigator: Mutch, David |
| Title: Defective DNA Mismatch Repair in Endometrial Cancers |
| ___________________________________________________________________________________________________ |
| Number: 201111175 |
Principal Investigator: Kuroki, Lindsay |
| Title: Pre- and Post-operative evaluation of FDG-PET/CT for detecting pelvic and para-aortic lymph node metastasis in uterine corpus cancer |
| ___________________________________________________________________________________________________ |
| Number: 201105123 |
Principal Investigator: Mutch, David |
| Title: SPORE In Endometrial Cancer |
| ___________________________________________________________________________________________________ |
| Number: 201108327 |
Principal Investigator: Wang-Gillam, Andrea |
| Title: Phase I Study of Erlotinib and Temsirolimus in Resistant Solid Malignancies |
| Description: The purpose of this study is to determine the maximum tolerated dose and side effects of the combination of two drugs, temsirolimus and erlotinib, used to treat solid tumor cancers. Temsirolimus is approved by the Food and Drug Administration (FDA) for treatment of renal cancer and is considered inv...MORE |
| ___________________________________________________________________________________________________ |
| Number: 201107068 |
Principal Investigator: Lockhart, A. Craig |
| Title: Phase I Safety and Pharmacokinetic Study of XRP6258 (Cabazitaxel) In Advanced Solid Tumor Patients with Varying Degrees of Hepatic Impairment |
| Description: The purpose of this study is to determine if Cabazitaxel is a safe treatment for patients with advanced cancers of different types who also have different levels of liver dysfunction. The highest safe dose of cabazitaxel (the maximum tolerated dose, or MTD) that can be given to patients with your le...MORE |
| ___________________________________________________________________________________________________ |
| Number: 201102462 |
Principal Investigator: Lockhart, A. Craig |
| Title: A Phase 1b, Multi-Center, Open Label, Uncontrolled, Serial Cohort, Dose Escalation Study of the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of Daily Oral Doses of ZSTK474 in Subjects with Advanced Solid Malignancies |
| Description: The main purpose of this study is to find out if the drug ZSTK474 is safe in people who have advanced cancers.
ZSTK474 is an investigational (experimental) drug. This means it has not been approved by the Food and Drug Administration (FDA). It is not currently on the market in any country. This stu...MORE |
| ___________________________________________________________________________________________________ |